Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.34 |
| ▸ | KMO | O15229 | 8/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | CCNC | P24863 | 1/20 | 0.32 |
| ▸ | CDK8 | P49336 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.32 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | FLT1 | P17948 | 1/20 | 0.31 |
| ▸ | TEK | Q02763 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1108278 | 0.81 | KDM4E (0.45) | CYP2A6ALDH1A1HPGDL3MBTL1PGR | |
| SCHEMBL2384472 | 0.79 | PIM1 (0.38) | CYP2A6KMOALDH1A1L3MBTL1CYP19A1 | |
| SCHEMBL24638508 | 0.75 | IKBKE (0.38) | KMOMEN1KMT2ASMN1; SMN2AAK1 | |
| SCHEMBL1098372 | 0.74 | CYP2A6 (0.49) | CYP2A6MEN1ALDH1A1HPGDKMT2A | |
| SCHEMBL1108279 | 0.74 | ALDH1A1 (0.37) | KMOALDH1A1HPGDAAK1 | |
| SCHEMBL1097848 | 0.74 | AAK1 (0.34) | KMOMEN1KMT2AAAK1 | |
| SCHEMBL210994 | 0.73 | KMO (0.42) | KMOMEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL6193707 | 0.72 | CYP2A6 (0.44) | CYP2A6ALDH1A1SMN1; SMN2L3MBTL1CYP19A1 | |
| SCHEMBL1466773 | 0.72 | CDK8 (0.46) | KMOMEN1ALDH1A1HPGDKMT2A | |
| SCHEMBL29607278 | 0.72 | CDK8 (0.46) | KMOMEN1ALDH1A1HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220241291-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | SOBI, INC. | 2022-08-04 | — | — | US | disclosed |
| US-11135227-B2 | Oxygen linked pyrimidine derivatives | CTI BIOPHARMA CORP. (US) | 2021-10-05 | — | — | US | disclosed |
| US-11135227-B2 | Oxygen linked pyrimidine derivatives | CTI BIOPHARMA CORP. (US) | 2021-10-05 | — | — | US | disclosed |
| US-20200071339-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | CTI BIOPHARMA CORP. (US) | 2020-03-05 | — | — | US | disclosed |
| US-20200071339-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | CTI BIOPHARMA CORP. (US) | 2020-03-05 | — | — | US | disclosed |
| US-20170112846-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | CTI BIOPHARMA CORP. (US) | 2017-04-27 | — | — | US | disclosed |
| US-20170112846-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | CTI BIOPHARMA CORP. (US) | 2017-04-27 | — | — | US | disclosed |
| US-20170112846-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | CTI BIOPHARMA CORP. (US) | 2017-04-27 | — | — | US | disclosed |
| US-9573964-B2 | Oxygen linked pyrimidine derivatives | CTI BIOPHARMA CORP. (US) | 2017-02-21 | — | — | US | disclosed |
| US-9573964-B2 | Oxygen linked pyrimidine derivatives | CTI BIOPHARMA CORP. (US) | 2017-02-21 | — | — | US | disclosed |
| US-8153632-B2 | Oxygen linked pyrimidine derivatives | S*BIO PTE LTD. (SG) | 2012-04-10 | — | — | US | disclosed |
| US-8153632-B2 | Oxygen linked pyrimidine derivatives | S*BIO PTE LTD. (SG) | 2012-04-10 | — | — | US | disclosed |
| CN-101360751-B | Oxygen linked pyrimidine derivatives | S BIO PTE LTD | 2011-09-14 | — | — | CN | disclosed |
| US-20090075999-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD. (SG) | 2009-03-19 | — | — | US | disclosed |
| US-20090075999-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD. (SG) | 2009-03-19 | — | — | US | disclosed |
| US-20090075999-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD. (SG) | 2009-03-19 | — | — | US | disclosed |
| CN-101360751-A | Oxygen linked pyrimidine derivatives | S BIO PTE LTD (SG) | 2009-02-04 | — | — | CN | disclosed |
| EP-1951729-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | S*Bio Pte Ltd (SG) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007058627-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD (SG) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007058627-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD (SG) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220241291-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | DPYD, TK2, TK1 | CYP2A6 2330/4885KMO 1161/4885MEN1 4071/4885 |
| US-20090075999-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | DPYD, TK2, TK1 | CYP2A6 2330/4885KMO 1161/4885MEN1 4071/4885 |
| US-20170112846-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | DPYD, TK2, TK1 | CYP2A6 2330/4885KMO 1161/4885MEN1 4071/4885 |
| US-11135227-B2 | Oxygen linked pyrimidine derivatives | DPYD, TK2, TK1 | CYP2A6 2330/4885KMO 1161/4885MEN1 4071/4885 |
| US-20200071339-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | DPYD, TK2, TK1 | CYP2A6 2330/4885KMO 1161/4885MEN1 4071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.